奥希替尼治疗晚期非小细胞肺癌35例

Abstract
Figure/Table
References
Related Citation (15)

[1]	Travis W D, Brambilla E, Muller-Hermelink H K. Pathology and genetics of tumors of the lung,pleura,thymus and heart World Health Organization classification of tumors[M]. Lyon:IARC Press,2004: 9-67.
[2]	Paez J G, Jnne P A, Lee J C, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinibtherapy[J]. Science,2004(304):1497-1500.
[3]	Lynch T J, Bell D W, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J]. N Engl J Med,2004(350):2129-2139.
[4]	Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers[J]. J Natl Cancer Inst,2005(97):339-346.
[5]	石远凯,孙燕,于金明,等. 中国晚期原发性肺癌诊治专家共识(2016版)[J].中国肺癌杂志, 2016,19(1):1-15.
[6]	Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR[J]. N Engl J Med,2010(362):2380-2388.
[7]	Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy asfirst-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial[J]. Lancet Oncol,2012(13):239-246.
[8]	Hu X, Han B, Gu A, et al. A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)[J]. Lung Cancer,2014,86(2):207-212.
[9]	Yu HA, Arcila M E, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers[J]. Clin Cancer Res,2013(19):2240-2247.
[10]	Jnne P A, Yang J C, Kim D W, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer[J]. N Engl J Med,2015,372(18):1689-1699.
[11]	Goss G, Tsai C M, Shepherd F A, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study[J]. Lancet Oncol,2016(14): S1470-2045.
[12]	Chong C R, Jnne P A. The quest to overcome resistance to EGFR-targeted therapies in cancer[J]. Nat Med,2013(19): 1389-1400.
[13]	Soria J, Kim S, Wu Y, et al. Gefitinib/chemotherapy vs chemotherapy in EGFR mutation-positive NSCLC resistant to first-line gefitinib: IMPRESS T790M subgroup analysis[J]. J Thorac Oncol,2015(10): S207.
[14]	Oh I J, Ban H J, Kim K S, et al. Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase Ⅱstudy[J]. Lung Cancer,2012(77):121-127.
[15]	Ballard P,Yates J W,Yang Z, et al. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain MetastasesModels, and Early Evidence of Clinical Brain Metastases Activity[J]. Clin Cancer Res,2016,22(20):5130-5140.
[16]	Ramalingam S, Yang J C, Lee C K, et al. LBA_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts[J]. J Thorac Oncol,2016,11(4 Suppl):S152.
[17]	Oxnard G R, Thress K S, Alden R S, et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer[J].J Clin Oncol,2016,34(28):3375-3382.